Public attention can accelerate adoption before evidence catches up
When a television segment and federal officials praised leucovorin as a possible aid for autistic children, American medicine responded not with caution but with velocity — prescriptions surged more than 2,000 percent in under a year, outpacing the science by a wide margin. The drug, approved only for a rare genetic disorder, has never been proven safe or broadly effective for autism spectrum disorder, yet the machinery of hope, media, and public authority moved faster than any clinical trial could follow. It is an old story wearing new clothes: the human need for answers arriving long before the answers themselves.
- A single television story in February 2025 and a wave of federal endorsements in September triggered one of the most dramatic prescription surges in recent pediatric medicine.
- Leucovorin prescribing rates among autistic children rocketed from 34 to 835 per 100,000 encounters — a 2,000% climb — without a single completed large-scale trial confirming its safety or effectiveness for autism.
- Families desperate for anything that might help their children communicate are making treatment decisions shaped more by media moments than by medical consensus.
- The FDA approved leucovorin in March 2026, but only for a rare genetic condition — not for autism — leaving a widening gap between public expectation and regulatory reality.
- Researchers are now calling for rigorous randomized trials and real-time prescribing surveillance, warning that the next media cycle could reshape clinical practice before evidence has any chance to catch up.
In early 2025, a television news segment featured a family whose autistic child had begun speaking more fluently after taking leucovorin, a processed form of folic acid. The story traveled fast. By autumn, when White House officials began publicly championing the drug as part of federal autism initiatives, prescriptions had already begun to climb. By November, they had reached 835 per 100,000 outpatient encounters involving autistic children — up from a steady baseline of just 34.
Researchers at UC San Diego documented the surge using electronic health records from more than 1,800 hospitals and 41,500 clinics, covering over 300 million patients. Their analysis of nearly 840,000 children with autism between 2023 and 2026 made the pattern unmistakable: each media event produced a new spike, with the steepest acceleration following federal officials' public statements in September 2025.
The troubling dimension is what the evidence actually supports. Small trials have hinted that leucovorin might benefit autistic children with specific folate-related deficiencies, but no large-scale study has confirmed its effectiveness or long-term safety for autism broadly. When the FDA approved leucovorin in March 2026, it was for cerebral folate transport deficiency — a rare genetic disease — not for autism spectrum disorder.
Lead researcher Dr. Joshua Rothman, whose findings appeared in JAMA Network Open, noted that the study tracked prescriptions, not outcomes — it cannot say whether any child was helped or harmed. What it reveals is a structural gap: the speed at which public attention reshapes medical practice versus the far slower pace at which rigorous evidence accumulates. His team is calling for large randomized trials and ongoing prescribing surveillance, framing this episode as a warning about what happens when hope, media, and authority move in concert — and science is left running to catch up.
In early 2025, a television news segment told the story of a family whose autistic child began speaking more fluently after taking leucovorin, a medication that is essentially a processed form of folic acid. The story resonated. By that autumn, when White House officials began publicly discussing the drug as part of their autism initiatives, something remarkable happened in American medicine: prescriptions for leucovorin among children with autism exploded.
Researchers at the University of California San Diego decided to measure what had actually occurred. Using a database of electronic health records from more than 1,800 hospitals and 41,500 clinics across the country—encompassing over 300 million patient records—they tracked prescribing patterns for 838,801 children with autism between January 2023 and January 2026. What they found was stark: prescribing rates had climbed more than 2,000 percent in less than a year.
For roughly two years, the medication had been prescribed at a steady, modest rate: about 34 times per 100,000 outpatient visits involving autistic children. Then, in early 2025, the line began to climb. By August, it had jumped to 335 prescriptions per 100,000 encounters. By November, it had nearly tripled again to 835 per 100,000. The timing was unmistakable. The initial surge followed the television news story in February. The second, steeper acceleration came after federal officials promoted the drug in September.
Yet here is what makes the finding troubling: leucovorin has not been proven safe or effective for autism. Small clinical trials have suggested that some children with autism who also have specific folate-related deficiencies might experience improvements in verbal communication. But large-scale studies confirming whether the drug actually works for broad use in autistic children, or what its long-term safety profile looks like, have never been completed. In March 2026, the FDA approved leucovorin—but only for a rare genetic neurological disease called cerebral folate transport deficiency, not for autism spectrum disorder.
Dr. Joshua Rothman, the lead researcher on the study published in JAMA Network Open, noted the paradox plainly: families of autistic children are desperate for treatments that might improve their child's communication and quality of life, especially when options feel limited. What the data revealed was how swiftly information traveling through news coverage, social media, and statements from public figures could reshape actual medical practice—long before the evidence was in.
"The timing was striking," Rothman said. "The increases began after a widely viewed media story and accelerated again after federal officials publicly discussed the medication. It highlights how rapidly clinical practice can shift when a treatment captures public attention."
The study itself did not measure whether leucovorin actually helped any of these children. It did not track outcomes. It only documented the surge in prescriptions and the media events that preceded it. The researchers also acknowledged that some prescriptions recorded in the database might not have been linked to a confirmed medical reason.
What the work does show is a gap—between the speed at which families and doctors adopt a treatment and the speed at which rigorous evidence accumulates. Rothman and his colleagues are calling for larger randomized clinical trials to determine whether leucovorin benefits specific groups of autistic children, and for continued monitoring of prescribing trends. "We now have a real-world example of how public attention can accelerate adoption of a therapy before the evidence fully catches up," he said. The question now is whether the medical system can generate the data families need to make truly informed choices—before the next media story reshapes practice again.
Citas Notables
The increases began after a widely viewed media story and accelerated again after federal officials publicly discussed the medication. It highlights how rapidly clinical practice can shift when a treatment captures public attention.— Dr. Joshua Rothman, UC San Diego School of Medicine
We now have a real-world example of how public attention can accelerate adoption of a therapy before the evidence fully catches up.— Dr. Joshua Rothman
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that prescriptions jumped so fast? Couldn't doctors have had good reasons?
The concern isn't that doctors are reckless. It's that the timing is too tight. The prescribing rate was stable for two years, then jumped 2,000% in months. That's not gradual adoption based on accumulating evidence—that's response to a news story and a White House statement.
But if the drug helps some kids, isn't it worth trying?
Maybe. But we don't actually know if it helps most kids with autism. Small trials suggested it might help kids with a specific folate deficiency. That's different from saying it works for autism broadly. And we have no long-term safety data.
So families are essentially experimenting on their children?
Not intentionally. Families are doing what parents do—searching for anything that might help their child communicate better. The problem is that media attention and official promotion created the impression of evidence that doesn't yet exist.
What should have happened instead?
Ideally, larger clinical trials would have been completed first. Then, if the evidence supported it, doctors and families would have had real data to work with. Instead, the treatment spread before the evidence caught up.
Is leucovorin dangerous?
We don't know. That's the point. It might be safe. It might have side effects we haven't documented yet because we haven't studied it carefully in this population. The absence of evidence of harm isn't the same as evidence of safety.
What happens now?
Researchers are calling for rigorous trials and better monitoring. But thousands of children are already taking the medication. The question is whether we can learn from this and do better next time.